Companies: 10,795·Total market cap: $144.5T
Silence Therapeutics plc

Silence Therapeutics plc

SLNNASDAQHealthcare● Active
$6.19
+$0.02(+0.24%)
Market Cap$292141968
P/E Ratio—
52W High$8.4
52W Low$4.19
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Silence Therapeutics plc (SLN) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001479615 · SLN · NASDAQ · as of Jun 8, 2026

Filing snapshot

248
Total Filings
EFFECT
Latest Form
2026-05-27
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001479615 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-05
Fiscal Year End
Mar 5, 2026
Accession No.
0001193125-26-092591
Primary Document
sln-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001479615 · Accession 0001193125-26-092591

Latest Key Filings

6-KQuarterly Report
6-K
2024-12-09
View 6-K on SEC
8-KCurrent Report
8-K
2026-05-18Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
EFFECTEFFECT
EFFECT
2026-05-27
View
424B5424B5
424B5
2026-05-27
View
8-KCurrent Report
8-K
2026-05-18
View
S-3Shelf Registration
S-3
2026-05-18
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
ARSARS
ARS
2026-04-29
View
DEF 14AProxy Statement
DEF 14A
2026-04-29
View
S-8Employee Stock Plan Registration
S-8
2026-03-05
View
10-KAnnual Report
10-K
2026-03-05
View
8-KCurrent Report
8-K
2026-03-05
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-09
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2025-12-22
View
8-K/ACurrent Report (Amended)
8-K/A
2025-12-22
View
8-KCurrent Report
8-K
2025-12-22
View
Showing 1–15 of 208 filingsForm 4 / 144 hidden· 248 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001479615  |  Exchange: NASDAQ · Healthcare

Silence Therapeutics plc (NASDAQ: SLN) has submitted 248 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001479615, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Silence Therapeutics plc's most comprehensive regulatory disclosure. The most recent Silence Therapeutics plc 10-K was filed on 2026-03-05 for fiscal year ending 2026. Historical SLN 10-K annual reports are available from 2010 through 2026.

Investors researching Silence Therapeutics plc SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
CAPR SEC Filings →ANRO SEC Filings →CTNM SEC Filings →LXEO SEC Filings →KYTX SEC Filings →AMRN SEC Filings →LYEL SEC Filings →ACIU SEC Filings →
→ SLN Financials→ SLN Earnings→ SLN Insider Trades

Frequently Asked Questions

SLN SEC Filings · 8 questions

Silence Therapeutics plc (SLN) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 248 filings and access original documents at no cost. Silence Therapeutics plc's CIK is 0001479615.

SLN SEC filingsSilence Therapeutics plc SEC documentsfind SLN 10-K